Plus Therapeutics, Inc. Share Price & Technical Analysis
PSTV · $6.59 (-4.35%)
Healthcare / Biotechnology
$6.59
-4.35%
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric bra…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
8% return in May, -10% avg return in past 3 year May month.
-6% return in 2026, -41% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -55% | 25% | -44% | 61% | 8% | – | – | – | – | – | – | – | -6% |
| 25 | 9% | -40% | 32% | -33% | -60% | -12% | 46% | -8% | 48% | -10% | 10% | -16% | -33% |
| 24 | 12% | -3% | -10% | -6% | 25% | -35% | 24% | -20% | 1% | 1% | -4% | -11% | -24% |
| 23 | 30% | -24% | -17% | -10% | 5% | -49% | 16% | 13% | -56% | -6% | 29% | 5% | -65% |
| 22 | -10% | 12% | -2% | -33% | -18% | -2% | -12% | 68% | -45% | 4% | -15% | -20% | -72% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$39.70M
P/E ratio
—
52W high
$23.50
52W low
$2.90
Volume
1,28,357
Beta
1.40
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Plus Therapeutics, Inc. share price today?
- Plus Therapeutics, Inc. (PSTV) last traded around $6.59 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PSTV have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PSTV. Download the app for real-time alerts.
- How can I analyze Plus Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.